{"id":"https://openalex.org/W2126573891","doi":"https://doi.org/10.1093/annonc/mdv490","title":"A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial","display_name":"A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial","alternate_titles":[],"publication_year":2015,"publication_date":"2015-10-20","ids":{"openalex":"https://openalex.org/W2126573891","doi":"https://doi.org/10.1093/annonc/mdv490","mag":"2126573891","pmid":"https://pubmed.ncbi.nlm.nih.gov/26483047"},"language":"en","primary_location":{"id":"doi:10.1093/annonc/mdv490","doi":"https://doi.org/10.1093/annonc/mdv490","is_oa":true,"landing_page_url":"https://doi.org/10.1093/annonc/mdv490","pdf_url":"https://www.annalsofoncology.org/article/S0923-7534(19)35343-8/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2126573891"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.annalsofoncology.org/article/S0923-7534(19)35343-8/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018881195","display_name":"Helga Hagman","orcid":"https://orcid.org/0000-0002-4427-1123","observed_orcids":["https://orcid.org/0000-0002-4427-1123"]},"institutions":[{"id":"https://openalex.org/I4210148116","display_name":"Ryhov Hospital J\u00f6nk\u00f6ping","ror":"https://ror.org/053xhbr86","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I4210148116"]}],"countries":["SE"],"is_corresponding":true,"raw_author_name":"H. Hagman","raw_affiliation_strings":["Department of Oncology, County Hospital Ryhov, J\u00f6nk\u00f6ping helga.hagman@med.lu.se","Department of Oncology, County Hospital Ryhov, J\u00f6nk\u00f6ping"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, County Hospital Ryhov, J\u00f6nk\u00f6ping helga.hagman@med.lu.se","institution_ids":["https://openalex.org/I4210148116"]},{"raw_affiliation_string":"Department of Oncology, County Hospital Ryhov, J\u00f6nk\u00f6ping","institution_ids":["https://openalex.org/I4210148116"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010199908","display_name":"Jan\u2010Erik Fr\u00f6din","orcid":"https://orcid.org/0000-0003-1985-2046","observed_orcids":["https://orcid.org/0000-0003-1985-2046"]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"J.-E. Fr\u00f6din","raw_affiliation_strings":["Department of Oncology, Karolinska University Hospital, Stockholm"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Karolinska University Hospital, Stockholm","institution_ids":["https://openalex.org/I1335113835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013720146","display_name":"\u00c5ke Berglund","orcid":"https://orcid.org/0000-0002-5240-3106","observed_orcids":["https://orcid.org/0000-0002-5240-3106"]},"institutions":[{"id":"https://openalex.org/I1342360035","display_name":"Uppsala University Hospital","ror":"https://ror.org/01apvbh93","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1342360035"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"\u00c5. Berglund","raw_affiliation_strings":["Department of Oncology, Uppsala University Hospital, Uppsala"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Uppsala University Hospital, Uppsala","institution_ids":["https://openalex.org/I1342360035"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077315656","display_name":"J. Sundberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210137844","display_name":"Sk\u00e5ne University Hospital","ror":"https://ror.org/02z31g829","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I4210137844"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"J. Sundberg","raw_affiliation_strings":["Department of Oncology, Sk\u00e5ne University Hospital, Lund/Malm\u00f6, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Sk\u00e5ne University Hospital, Lund/Malm\u00f6, Sweden","institution_ids":["https://openalex.org/I4210137844"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006731302","display_name":"L. W. Vestermark","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801498763","display_name":"Odense University Hospital","ror":"https://ror.org/00ey0ed83","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2801498763"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"L.W. Vestermark","raw_affiliation_strings":["Department of Oncology, Odense University Hospital, Odense, Denmark","Dept. of Oncology Odense University Hospital Odense Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Odense University Hospital, Odense, Denmark","institution_ids":["https://openalex.org/I2801498763"]},{"raw_affiliation_string":"Dept. of Oncology Odense University Hospital Odense Denmark","institution_ids":["https://openalex.org/I2801498763"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001343408","display_name":"Martin Albertsson","orcid":"https://orcid.org/0000-0002-7123-3376","observed_orcids":["https://orcid.org/0000-0002-7123-3376"]},"institutions":[{"id":"https://openalex.org/I4210151885","display_name":"Link\u00f6ping University Hospital","ror":"https://ror.org/05h1aye87","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I4210151885"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"M. Albertsson","raw_affiliation_strings":["Department of Oncology, Link\u00f6ping University Hospital, Link\u00f6ping"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Link\u00f6ping University Hospital, Link\u00f6ping","institution_ids":["https://openalex.org/I4210151885"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051996271","display_name":"Eva Fernebro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210157561","display_name":"V\u00e4xj\u00f6 Kommun","ror":"https://ror.org/04hwmbc03","country_code":"SE","type":"government","lineage":["https://openalex.org/I4210157561"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"E. Fernebro","raw_affiliation_strings":["Department of Oncology, V\u00e4xj\u00f6 Hospital, V\u00e4xj\u00f6, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, V\u00e4xj\u00f6 Hospital, V\u00e4xj\u00f6, Sweden","institution_ids":["https://openalex.org/I4210157561"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5013696063","display_name":"Anna Johnsson","orcid":"https://orcid.org/0000-0001-9347-5336","observed_orcids":["https://orcid.org/0000-0001-9347-5336"]},"institutions":[{"id":"https://openalex.org/I4210137844","display_name":"Sk\u00e5ne University Hospital","ror":"https://ror.org/02z31g829","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I4210137844"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"A. Johnsson","raw_affiliation_strings":["Department of Oncology, Sk\u00e5ne University Hospital, Lund/Malm\u00f6, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Sk\u00e5ne University Hospital, Lund/Malm\u00f6, Sweden","institution_ids":["https://openalex.org/I4210137844"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5018881195"],"corresponding_institution_ids":["https://openalex.org/I4210148116"],"apc_list":{"value":5080,"currency":"USD","value_usd":5080},"apc_paid":null,"fwci":3.3142,"has_fulltext":true,"cited_by_count":57,"citation_normalized_percentile":{"value":0.94290283,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"27","issue":"1","first_page":"140","last_page":"147"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10335","display_name":"Colorectal Cancer Surgical Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9909999966621399},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.9819999933242798},{"id":"https://openalex.org/keywords/kras-mutation-status","display_name":"KRAS mutation status","score":0.8270000219345093},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":1.0},{"id":"https://openalex.org/keywords/metronomic-capecitabine","display_name":"metronomic capecitabine","score":0.9850000143051147},{"id":"https://openalex.org/keywords/xelox","display_name":"XELOX","score":0.8169999718666077},{"id":"https://openalex.org/keywords/folfox","display_name":"FOLFOX","score":0.9039999842643738},{"id":"https://openalex.org/keywords/xeliri","display_name":"XELIRI","score":0.8510000109672546},{"id":"https://openalex.org/keywords/folfiri","display_name":"FOLFIRI","score":0.9729999899864197},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9750000238418579},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.4959999918937683},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.5509999990463257},{"id":"https://openalex.org/keywords/biomarker-guided-therapy","display_name":"biomarker-guided therapy","score":0.5350000262260437}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9405538439750671},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8216491937637329},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.7949549555778503},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7478224635124207},{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.7170411348342896},{"id":"https://openalex.org/C2776705615","wikidata":"https://www.wikidata.org/wiki/Q1389369","display_name":"FOLFIRI","level":5,"score":0.6696946620941162},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.6162182092666626},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5978424549102783},{"id":"https://openalex.org/C2778260052","wikidata":"https://www.wikidata.org/wiki/Q117636","display_name":"FOLFOX","level":5,"score":0.5766025185585022},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.5378519892692566},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4835509955883026},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.45118317008018494},{"id":"https://openalex.org/C204243189","wikidata":"https://www.wikidata.org/wiki/Q1363085","display_name":"Randomization","level":3,"score":0.4509248435497284},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.338815301656723},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.33465421199798584},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2972242832183838},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.1707799732685089},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.07643145322799683}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D016016","descriptor_name":"Proportional Hazards Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016283","descriptor_name":"Proto-Oncogene Proteins p21(ras)","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053208","descriptor_name":"Kaplan-Meier Estimate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059250","descriptor_name":"Administration, Metronomic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060046","descriptor_name":"Maintenance Chemotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060828","descriptor_name":"Induction Chemotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1093/annonc/mdv490","doi":"https://doi.org/10.1093/annonc/mdv490","is_oa":true,"landing_page_url":"https://doi.org/10.1093/annonc/mdv490","pdf_url":"https://www.annalsofoncology.org/article/S0923-7534(19)35343-8/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},{"id":"pmid:26483047","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26483047","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of oncology : official journal of the European Society for Medical Oncology","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:sdu.dk:openaire_cris_publications/ba37ce4a-5fd5-47c9-aa09-0f3feb31c010","doi":null,"is_oa":false,"landing_page_url":"https://portal.findresearcher.sdu.dk/da/publications/ba37ce4a-5fd5-47c9-aa09-0f3feb31c010","pdf_url":null,"source":{"id":"https://openalex.org/S4306400423","display_name":"University of Southern Denmark Research Portal (University of Southern Denmark)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I177969490","host_organization_name":"University of Southern Denmark","host_organization_lineage":["https://openalex.org/I177969490"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hagman, H, Fr\u00f6din, J-E, Berglund, \u00c5, Sundberg, J, Weber Vestermark, L, Albertsson, M, Fernebro, E & Johnsson, A 2016, 'A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer : the Nordic ACT2 trial', Annals of Oncology, vol. 27, no. 1, pp. 140-147. https://doi.org/10.1093/annonc/mdv490","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:lup.lub.lu.se:ec3e1c14-a029-4ba0-8444-6f6421ef4074","doi":null,"is_oa":false,"landing_page_url":"https://lup.lub.lu.se/record/ec3e1c14-a029-4ba0-8444-6f6421ef4074","pdf_url":null,"source":{"id":"https://openalex.org/S4306400536","display_name":"Lund University Publications (Lund University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I187531555","host_organization_name":"Lund University","host_organization_lineage":["https://openalex.org/I187531555"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Annals of Oncology; 27(1), pp 140-147 (2016)","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1093/annonc/mdv490","doi":"https://doi.org/10.1093/annonc/mdv490","is_oa":true,"landing_page_url":"https://doi.org/10.1093/annonc/mdv490","pdf_url":"https://www.annalsofoncology.org/article/S0923-7534(19)35343-8/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320313624","display_name":"Sk\u00e5ne County Council's Research and Development Foundation","ror":null},{"id":"https://openalex.org/F4320335417","display_name":"Futurum - Akademin f\u00f6r H\u00e4lsa och V\u00e5rd, Region J\u00f6nk\u00f6pings l\u00e4ns","ror":"https://ror.org/046p5eg67"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2126573891.pdf","grobid_xml":"https://content.openalex.org/works/W2126573891.grobid-xml"},"referenced_works_count":14,"referenced_works":["https://openalex.org/W81945182","https://openalex.org/W1919810009","https://openalex.org/W2038262098","https://openalex.org/W2081957151","https://openalex.org/W2095201384","https://openalex.org/W2103789431","https://openalex.org/W2111031611","https://openalex.org/W2116978520","https://openalex.org/W2128059540","https://openalex.org/W2137417501","https://openalex.org/W2153211112","https://openalex.org/W2156438240","https://openalex.org/W2162896805","https://openalex.org/W2600577610"],"related_works":["https://openalex.org/W2591049751","https://openalex.org/W2600577610","https://openalex.org/W2241925421","https://openalex.org/W2162896805","https://openalex.org/W2611721360","https://openalex.org/W4214691994","https://openalex.org/W4250802977","https://openalex.org/W2259669113","https://openalex.org/W2116978520","https://openalex.org/W2054122365"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2126573891","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":9}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2016-06-24T00:00:00"}
